

Special Issue

Extracellular Vesicle-Based Vaccines

Message from the Guest Editors

We are slowly progressing from a pandemic to the “new normal” that came about due to the help of novel vaccine technologies. We would like to invite you to share your ideas concerning recent developments that came about during this period focusing on extracellular vesicles (membranous and non-membranous nanovesicles), viral particles, and synthetic particles able to elicit a preventive immune response. In this Special Issue, we will bundle studies and reviews that elucidate the use of extracellular vesicles for vaccination purposes, focusing on their use as a multicargo carrier that will be important in the development of next-generation vaccines.

Guest Editors

Dr. Koen Breyne

Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA

Dr. Taral Rameshchand Lunavat

1. Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA

2. Department of Biomedicine, University of Bergen, 5019 Bergen, Norway

Deadline for manuscript submissions

closed (1 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/115520

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).